At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 246 enrolled
Drug / intervention
Carboxymethylcellulose sodium and Glycerin +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear
In Brief
A Phase 3 clinical trial evaluating Carboxymethylcellulose sodium and Glycerin and Carboxymethylcellulose sodium for Ametropia. Completed, enrolled 246 participants across 1 site.
Detailed Summary
Testing the Safety and Acceptability of Using a Rewetting Drop with Contact Lenses
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmetropia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedJun 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedJun 5, 2008
Enrollment StartMar 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.1 years ago
Interventions
Carboxymethylcellulose sodium and Glycerindevice
Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
Carboxymethylcellulose sodiumdevice
Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.